Tags

Type your tag names separated by a space and hit enter

Cannabidiol monotherapy for treatment-resistant schizophrenia.
J Psychopharmacol. 2006 Sep; 20(5):683-6.JP

Abstract

Cannabidiol (CBD), one of the major products of the marijuana plant, is devoid of marijuana's typical psychological effects. In contrast, potential antipsychotic efficacy has been suggested based on preclinical and clinical data (Zuardi et al., 2002). In this report, we further investigated the efficacy and safety of CBD monotherapy in three patients with treatment-resistant schizophrenia (TRS). This was an in-patient study. All patients were given placebo for the initial 5 days, and from the 6th to 35th day (inclusive) they received CBD (initial oral dose of 40 mg reaching 1280 mg/day). On the 36th day, CBD treatment was discontinued and replaced by placebo for 5 days, which was subsequently switched to olanzapine for over 15 days. Efficacy, tolerability and side effects were assessed. One patient showed mild improvement, but two patients didn't show any improvement during CBD monotherapy. All patients tolerated CBD very well and no side effects were reported. These preliminary data suggest that CBD monotherapy may not be effective for TRS.

Authors+Show Affiliations

Department of Neuropsychiatry and Medical Psychology, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16401651

Citation

Zuardi, Antonio Waldo, et al. "Cannabidiol Monotherapy for Treatment-resistant Schizophrenia." Journal of Psychopharmacology (Oxford, England), vol. 20, no. 5, 2006, pp. 683-6.
Zuardi AW, Hallak JE, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20(5):683-6.
Zuardi, A. W., Hallak, J. E., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. Journal of Psychopharmacology (Oxford, England), 20(5), 683-6.
Zuardi AW, et al. Cannabidiol Monotherapy for Treatment-resistant Schizophrenia. J Psychopharmacol. 2006;20(5):683-6. PubMed PMID: 16401651.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol monotherapy for treatment-resistant schizophrenia. AU - Zuardi,Antonio Waldo, AU - Hallak,Jaime E C, AU - Dursun,Serdar Murat, AU - Morais,Sílvio L, AU - Sanches,Rafael Faria, AU - Musty,Richard E, AU - Crippa,José Alexandre S, Y1 - 2006/01/09/ PY - 2006/1/13/pubmed PY - 2006/10/20/medline PY - 2006/1/13/entrez SP - 683 EP - 6 JF - Journal of psychopharmacology (Oxford, England) JO - J Psychopharmacol VL - 20 IS - 5 N2 - Cannabidiol (CBD), one of the major products of the marijuana plant, is devoid of marijuana's typical psychological effects. In contrast, potential antipsychotic efficacy has been suggested based on preclinical and clinical data (Zuardi et al., 2002). In this report, we further investigated the efficacy and safety of CBD monotherapy in three patients with treatment-resistant schizophrenia (TRS). This was an in-patient study. All patients were given placebo for the initial 5 days, and from the 6th to 35th day (inclusive) they received CBD (initial oral dose of 40 mg reaching 1280 mg/day). On the 36th day, CBD treatment was discontinued and replaced by placebo for 5 days, which was subsequently switched to olanzapine for over 15 days. Efficacy, tolerability and side effects were assessed. One patient showed mild improvement, but two patients didn't show any improvement during CBD monotherapy. All patients tolerated CBD very well and no side effects were reported. These preliminary data suggest that CBD monotherapy may not be effective for TRS. SN - 0269-8811 UR - https://www.unboundmedicine.com/medline/citation/16401651/Cannabidiol_monotherapy_for_treatment_resistant_schizophrenia_ L2 - https://journals.sagepub.com/doi/10.1177/0269881106060967?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -